Clinical Performance of QIAGEN Fibroblast Growth Factor Receptor (FGFR) Assay for the Detection of FGFR Alterations in Erdafitinib-Treated Patients with Metastatic or Locally Advanced, Surgically Unresectable, Urothelial Cancer

Major C, Wang S, Burgess M, English A, Sweeney M, Hartmann A (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Journal of Molecular Diagnostics American Society for Investigative Pathology (ASIP): Journal of Molecular Diagnostics

Publisher: ELSEVIER SCIENCE INC

City/Town: NEW YORK

Pages Range: S57-S57

Conference Proceedings Title: JOURNAL OF MOLECULAR DIAGNOSTICS

Event location: Hong Kong, HONG KONG

Authors with CRIS profile

Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie

Involved external institutions

QIAGEN Ltd. GB United Kingdom (GB) Janssen Pharmaceutica NV BE Belgium (BE)

How to cite

APA:

Major, C., Wang, S., Burgess, M., English, A., Sweeney, M., & Hartmann, A. (2019). Clinical Performance of QIAGEN Fibroblast Growth Factor Receptor (FGFR) Assay for the Detection of FGFR Alterations in Erdafitinib-Treated Patients with Metastatic or Locally Advanced, Surgically Unresectable, Urothelial Cancer. In JOURNAL OF MOLECULAR DIAGNOSTICS (pp. S57-S57). Hong Kong, HONG KONG: NEW YORK: ELSEVIER SCIENCE INC.

MLA:

Major, C., et al. "Clinical Performance of QIAGEN Fibroblast Growth Factor Receptor (FGFR) Assay for the Detection of FGFR Alterations in Erdafitinib-Treated Patients with Metastatic or Locally Advanced, Surgically Unresectable, Urothelial Cancer." Proceedings of the 2nd Association-for-Molecular-Pathology (AMP) Global Congress on Molecular Pathology - Evidence-Based Precision Medicine, Hong Kong, HONG KONG NEW YORK: ELSEVIER SCIENCE INC, 2019. S57-S57.

BibTeX: Download